艾美捷科技代理Boneslices品牌全系列产品

Boneslices是一家来自丹麦的公司，专注于生产牛皮质骨片。Boneslices公司提供用于200um, 400um厚度破骨细胞骨吸收功能检测Boneslice骨切片，适用于96孔板检测。

▍Boneslices产品介绍

在开始陷窝实验前，需用培养基对骨切片进行复水处理。由外周血单核细胞（PBMC）或共培养体系生成的成熟/未成熟破骨细胞，均可接种于骨切片表面。根据破骨细胞的成熟状态及存在因子的差异，吸收陷窝将在3-14天内形成。通过抗酒石酸酸性磷酸酶（TRAcP）活性检测可观察破骨细胞数量，而甲苯胺蓝染色则可显现吸收陷窝与吸收沟的形成（见图2）。

▍产品参数

产品描述：本品为用于破骨细胞骨吸收实验的皮质骨切片。

规格参数：直径：6mm（适配96孔板）

厚度：0.2mm（最适用免疫荧光、共聚焦显微镜及延时记录）；0.4mm（最适用下游分析）

运输条件：骨切片在室温环境下运输。

用途说明：牛皮质骨切片专为96孔板中的破骨细胞陷窝/骨吸收实验设计。

艾美捷科技特约代理BioPorto Diagnostics A/S公司产品。

BioPorto Diagnostics A/S公司成立于2001年，是丹麦一家专门生产抗体和基于抗体的各种生物产品的公司。BioPorto拥有Bioporto Diagnostics和Antibodyshop两个品牌，分别侧重于诊断试剂盒和抗体产品。在30多个国家有代理商，产品销售网络遍布全球，99%以上为出口销售。BioPorto Diagnostics旗下产品主要为几种临床快速诊断试剂盒，包括诊断早期急性肾损伤的NGAL ELISA kit，Gc-globulin ELISA kit ，评估原发性免疫缺陷的MBL Oligomer ELISA kit，同时还有相关其他种属的科研用试剂盒和抗原抗体。其最新推出的产品有检测人体血浆中的活性蛋白C-蛋白C抑制物(APC-PCI)复合物的APC-PCI ELISA kit，高纯度人IgE单克隆抗体，以及Glucagon-like peptide-1和Exendin-4相关的单抗。

BioPorto Diagnostics A/S is an in-vitro diagnostics company that provides healthcare professionals in clinical and research settings a range of diagnostic tests and antibodies. Our pioneering product portfolio includes assays for underserved disease states such as NGAL for acute kidney injury. We sell our products in more than 80 countries through diverse sales channels and partners. BioPorto has its headquarters in Copenhagen, Denmark and is listed on the Nasdaq Copenhagen stock exchange.

艾美捷科技特约代理Avidity Biosciences公司产品。

Avidity Biosciences公司位于美国加州La Jolla，是一家专门从事抗体寡核苷酸结合物（AOC™）技术开发的生物技术公司，此项技术结合了单抗组织选择性和寡核苷酸疗法的精确性，克服了寡核苷酸给药屏障。

Avidity Biosciences is a privately-held biotech company pioneering Antibody Oligonucleotide Conjugates (AOC™). AOCs combine the tissue selectivity of monoclonal antibodies and the precision of oligonucleotide-based therapeutics to overcome barriers to the delivery of oligonucleotides and target genetic drivers of disease.

Antibody oligonucleotide conjugate (AOC™) technology

Avidity’s antibody oligonucleotide conjugate (AOC™) technology utilizes antibodies to target cells and tissues of interest and facilitate the uptake and internalization of oligonucleotide payloads. By combining the cellular and tissue selectivity of antibodies with the selectivity and efficiency of oligo-based approaches, Avidity has demonstrated modulation of disease-related RNAs in diverse cell types and tissues including muscle, heart, liver, tumors and immune cells.